The Melanoma Breakthrough: What's at Stake Beyond Wall Street's Gains The news cycle has been abuzz with the stunning 177% surge in Moderna shares, driven by a Phase 3 trial breakthrough in cancer treatment.
This development is more than just a stock market phenomenon; it marks a significant turning point in the fight against cancer.
At its core, the news is about intismeran, Moderna's personalized mRNA cancer vaccine that has demonstrated significant promise in reducing melanoma recurrence.